Clinical Trial Update: Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating the combination of letrozole, everolimus, and TRC105 in postmenopausal women with hormone receptor-positive and HER2-negative breas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Everolimus (everolimus)
• Letrozole (letrozole)
• TRC105 (carotuximab)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-08-21